Gregory J. Babcock

6.4k citations

49 papers · 4.7k indexed · 1 hit paper · h-index 29

Co-authors: David A. Thorley‐Lawson L L Decker Mark S. Volk Donna M. Ambrosino Joseph Sodroski William D. Thomas Michael FarzanBin Yang
Topics: Viral-associated cancers and disorders (13 papers)Monoclonal and Polyclonal Antibodies Research (10 papers)HIV Research and Treatment (8 papers)
Cited by: Virology Infectious Diseases Oncology
Journals: Proceedings of the National Academy of Sciences Journal of Biological Chemistry Journal of Clinical Investigation
Partner nations: United States Singapore Hong Kong

In The Last Decade

Gregory J. Babcock

49 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EBV Persistence in Memory B Cells In Vivo

1998 631 citations Gregory J. Babcock, L L Decker et al. Immunity profile →

Peers

Countries citing papers authored by Gregory J. Babcock

Since Specialization

Citations

This map shows the geographic impact of Gregory J. Babcock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory J. Babcock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory J. Babcock more than expected).

Fields of papers citing papers by Gregory J. Babcock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory J. Babcock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory J. Babcock. The network helps show where Gregory J. Babcock may publish in the future.

Co-authorship network of co-authors of Gregory J. Babcock

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory J. Babcock. A scholar is included among the top collaborators of Gregory J. Babcock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory J. Babcock. Gregory J. Babcock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development of an antibody fused with an antimicrobial peptide targeting Pseudomonas aeruginosa: A new approach to prevent and treat bacterial infections 2023 ·PLoS Pathogens ·Kenneth D. Johnson,James C. Delaney,Thomas Guillard,Fany Reffuveille,Jennifer Varin,Kai Li,Andrew M. Wollacott,Eric Frapy,Surin K. Mong,Hamid Tissire,Karthik Viswanathan,Fayçal Touti,Gregory J. Babcock,Zachary Shriver,Bradley L. Pentelute,Obadiah J. Plante,David Skurnik	17
2	Expression of SARS coronavirus 1 spike protein from a herpesviral vector induces innate immune signaling and neutralizing antibody responses 2021 ·Virology ·Evelyn A. Kurt‐Jones,Timothy Dudek,Daisuke Watanabe,(unknown),(unknown),Shenghua Zhou,Lu-Cheng Cao,Thomas C. Greenough,Gregory J. Babcock,Fernando Dı́az,Hyung Suk Oh,Changhong Zhou,Robert W. Finberg,David M. Knipe	4
3	Extending human IgG half-life using structure-guided design 2018 ·mAbs ·(unknown),Boopathy Ramakrishnan,Kristin Narayan,Andrew M. Wollacott,Gregory J. Babcock,Zachary Shriver,Karthik Viswanathan	76
4	Preclinical evaluation of VIS513, a therapeutic antibody against dengue virus, in non-human primates 2017 ·Antiviral Research ·Eugenia Z. Ong,(unknown),Hwee Cheng Tan,Luke N. Robinson,Kirk J. Rowley,Alexander Viloria Winnett,Sven N. Hobbie,Zachary Shriver,Gregory J. Babcock,Eng Eong Ooi	21
5	High-Throughput Sequencing Analysis of Post-Liver Transplantation HCV E2 Glycoprotein Evolution in the Presence and Absence of Neutralizing Monoclonal Antibody 2014 ·PLoS ONE ·Gregory J. Babcock,Sowmya Iyer,Heidi L. Smith,Yang Wang,Kirk J. Rowley,Donna M. Ambrosino,Phillip D. Zamore,Brian G. Pierce,Deborah C. Molrine,Zhiping Weng	18
6	Identification of Human Monoclonal Antibodies Specific for Human SOD1 Recognizing Distinct Epitopes and Forms of SOD1 2013 ·PLoS ONE ·Teresa J. Broering,Hongyan Wang,Naomi K. Boatright,Yang Wang,(unknown),(unknown),(unknown),Can Kayatekin,Daryl A. Bosco,C. Robert Matthews,Donna M. Ambrosino,Zuoshang Xu,Gregory J. Babcock	14
7	Human Monoclonal Antibody HCV1 Effectively Prevents and Treats HCV Infection in Chimpanzees 2012 ·PLoS Pathogens ·Trevor J. Morin,Teresa J. Broering,Brett Leav,Barbra M. Blair,Kirk J. Rowley,(unknown),Yang Wang,Peter Cheslock,(unknown),David B. Olsen,(unknown),Gyöngyi Szabó,Robert W. Finberg,Robert H. Purcell,Robert E. Lanford,Donna M. Ambrosino,Deborah C. Molrine,Gregory J. Babcock	133
8	Cd81/Cd9 Tetraspanins Aid Plasmacytoid Dendritic Cells in Recognition of Hepatitis C Virus–Infected Cells And Induction of Interferon-Alpha 2012 ·Hepatology ·Shuye Zhang,Karen Kodys,Gregory J. Babcock,Gyöngyi Szabó	36
9	G glycoprotein amino acid residues required for human monoclonal antibody RAB1 neutralization are conserved in rabies virus street isolates 2011 ·Antiviral Research ·Yang Wang,Kirk J. Rowley,(unknown),Susan Sloan,Donna M. Ambrosino,Gregory J. Babcock	25
10	Identification and Characterization of Broadly Neutralizing Human Monoclonal Antibodies Directed against the E2 Envelope Glycoprotein of Hepatitis C Virus 2009 ·Journal of Virology ·Teresa J. Broering,(unknown),Naomi K. Boatright,Susan Sloan,Frantisek Sandor,William D. Thomas,Gyöngyi Szabó,Robert W. Finberg,Donna M. Ambrosino,Gregory J. Babcock	148
11	Human Monoclonal Antibodies Neutralize Toxins Produced by Epidemic Strains of Clostridium difficile 2005 ·Gregory J. Babcock	2
12	N-linked glycosylation in the CXCR4 N-terminus inhibits binding to HIV-1 envelope glycoproteins 2004 ·Virology ·Jianbin Wang,Gregory J. Babcock,Hyeryun Choe,Michael Farzan,Joseph Sodroski,Dana Gabuzda	36
13	Detection of EBV Infection at the Single-Cell Level: Precise Quantitation of Virus-Infected Cells In Vivo 2003 ·Humana Press eBooks ·Gregory J. Babcock,Emily Miyashita‐Lin,David A. Thorley‐Lawson	5
14	Stimulation of Enveloped Virus Infection by β-Amyloid Fibrils 2002 ·Journal of Biological Chemistry ·Woj M. Wojtowicz,Michael Farzan,John L. Joyal,Kara Carter,Gregory J. Babcock,David I. Israel,Joseph Sodroski,Tajib A. Mirzabekov	59
15	Ligand Binding Characteristics of CXCR4 Incorporated into Paramagnetic Proteoliposomes 2001 ·Journal of Biological Chemistry ·Gregory J. Babcock,Tajib A. Mirzabekov,Woj M. Wojtowicz,Joseph Sodroski	84
16	EBV Persistence Involves Strict Selection of Latently Infected B Cells 2000 ·The Journal of Immunology ·Alexandra Joseph,Gregory J. Babcock,David A. Thorley‐Lawson	79
17	The Expression Pattern of Epstein-Barr Virus Latent Genes In Vivo Is Dependent upon the Differentiation Stage of the Infected B Cell 2000 ·Immunity ·Gregory J. Babcock,(unknown),(unknown)	383
18	Epstein-Barr Virus–Infected Resting Memory B Cells, Not Proliferating Lymphoblasts, Accumulate in the Peripheral Blood of Immunosuppressed Patients 1999 ·The Journal of Experimental Medicine ·Gregory J. Babcock,L L Decker,Richard B. Freeman,David A. Thorley‐Lawson	257
19	EBV Persistence in Memory B Cells In Vivobreakdown → 1998 ·Immunity ·Gregory J. Babcock,L L Decker,Mark S. Volk,David A. Thorley‐Lawson	631
20	Is EBV Persistence In Vivo a Model for B Cell Homeostasis? 1996 ·Immunity ·Gulfaraz Khan,(unknown),Bin Yang,Gregory J. Babcock,(unknown)	149

About Gregory J. Babcock

Gregory J. Babcock is a scholar working on Virology, Immunology and Infectious Diseases, having authored 49 papers that have together received 4.7k indexed citations. Recurring topics across this work include Viral-associated cancers and disorders (13 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and HIV Research and Treatment (8 papers). The work is most often cited by research in Virology (456 citations), Infectious Diseases (1.6k citations) and Oncology (2.3k citations). Gregory J. Babcock has collaborated with scholars based in United States, Singapore and Hong Kong. Frequent co-authors include David A. Thorley‐Lawson, L L Decker, Mark S. Volk, Donna M. Ambrosino, Joseph Sodroski, William D. Thomas, Michael Farzan, Bin Yang, Richard B. Freeman and Alexandra Joseph. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact